3 results
Approved WMORecruiting
The current study has been designed to demonstrate that MOCA using Flebogrif is not inferior to EVLA for the treatment of GSV insufficiency.
Approved WMOCompleted
The primary scientific aim of the PROMINENT study is to assess whether treatment with the selective peroxisome proliferator activated receptor modulator alpha (SPPARM-α), pemafibrate, will prevent myocardial infarction (MI), ischemic stroke,…
Approved WMORecruiting
In 2013 the Boston Scientific VERCISE System has obtained regulatory approval for use in the European Union, CE mark was granted for the treatment of intractable primary and secondary dystonia.The objective of the study is to compile characteristics…